Iambic Therapeutics, Inc.

Iambic Therapeutics, Inc. (IAM) priced its initial public offering on Oct 15, 2026 at $16.00 per share, within its $15.00–$17.00 range, raising $150M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $758.4M. J.P. Morgan was lead-left underwriter, joined by Jefferies, BofA Securities and Citigroup.

Status

IPO

Ticker

IAM

Exchange

Nasdaq Global Select

Priced

Oct 15, 2026

IPO price

$16.00

Price range

$15.00–$17.00

Raised

$150M

Market cap at IPO price

$758.4M

First filed

Sep 21, 2026

Underwriters

J.P. Morgan, Jefferies, BofA Securities and Citigroup

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.